SCHEMBL265744

SCHEMBL265744

COCCOc1ccc(NC(=O)c2cccc(CCl)c2)c(C(=O)OC)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.53
ALDH1A1 P00352 6/20 0.53
NPC1 O15118 4/20 0.53
RAB9A P51151 4/20 0.53
SMN1; SMN2 Q16637 4/20 0.53
HPGD P15428 3/20 0.53
AKR1C2 P52895 2/20 0.48
AKR1C1 Q04828 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.47
GAA P10253 2/20 0.44
MAPK14 Q16539 1/20 0.44
MAPT P10636 3/20 0.43
LMNA P02545 2/20 0.43
POLB P06746 2/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
TSHR P16473 2/20 0.43
THRB P10828 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
MRGPRX4 Q96LA9 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL266632 0.89 SMN1; SMN2 (0.54) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL265743 0.85 KDM4E (0.50) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL267492 0.85 MET (0.53) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL268374 0.84 ALDH1A1 (0.55) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL267931 0.83 HPGD (0.57) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL266398 0.82 AKR1C2 (0.54) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL267004 0.81 KDR (0.44) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL266810 0.81 KDM4E (0.54) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL268838 0.78 KDM4E (0.49) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL7122743 0.77 PYGM (0.59) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 KDM4E 4468/4885ALDH1A1 3022/4885NPC1 102/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 KDM4E 4535/4885ALDH1A1 2872/4885NPC1 115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.